Company news
Indaptus Therapeutics, Inc. (NASDAQ:INDP) news
Indaptus Therapeutics, Inc. news releases on 6ix. Latest, Feb 14, 2023: Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
Press releases — page 2
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
February 13, 2023
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
February 6, 2023
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
December 12, 2022
Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 9, 2022
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 7, 2022
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
May 18, 2022
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 20, 2022
Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer
January 2, 2022
Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors
November 30, 2021
Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 14, 2021